Opinion|Videos|July 29, 2024
Clinical Pearls for Community Oncologist Treating LR-MDS
Author(s)Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD, provides advice to community oncologists on the treatment of anemia for patients with lower-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What clinical pearls could you share to community oncologists in the treatment of anemia for patients with LR-MDS?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
3
Key Takeaways From DeLLphi-305 at ESMO 2026
4
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
5